AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth Care
Hematopoietic Stem CellsHematopoietic Stem Cell TransplantationStem CellsHematopoiesisStem Cell TransplantationGraft SurvivalCell DifferentiationStem Cell NicheHematopoietic Stem Cell MobilizationCell LineageTransplantation, HomologousAntigens, CD34Adult Stem CellsEmbryonic Stem CellsBone Marrow CellsColony-Forming Units AssayGraft vs Host DiseaseMice, Inbred C57BLStem Cell FactorPluripotent Stem CellsMultipotent Stem CellsTransplantation ConditioningFlow CytometryBone MarrowTransplantation, AutologousBone Marrow TransplantationFetal BloodCells, CulturedCell ProliferationCell SeparationHematologic NeoplasmsHematopoietic SystemMesonephrosInduced Pluripotent Stem CellsMesenchymal Stromal CellsNeural Stem CellsMesenchymal Stem Cell TransplantationMice, SCIDFetal Stem CellsTransplantation ChimeraCord Blood Stem Cell TransplantationWhole-Body IrradiationMice, Inbred NODProto-Oncogene Proteins c-kitLentivirusGraft Occlusion, VascularCell Culture TechniquesTime FactorsChimerismTransduction, GeneticLeukemiaMyeloid Progenitor CellsGranulocyte Colony-Stimulating FactorPeripheral Blood Stem Cell TransplantationTreatment OutcomeGenetic VectorsRetroviridaeMice, KnockoutTissue DonorsMice, TransgenicAntigens, CDLymphopoiesisRadiation ChimeraNeoplastic Stem CellsHematopoiesis, ExtramedullaryHistocompatibility TestingCell DivisionHistocompatibilityRegenerationSignal TransductionStromal CellsGenetic TherapyBusulfanAntigens, LyAntigens, CD38ThrombopoietinEmbryo, MammalianRetrospective StudiesStem Cell ResearchReverse Transcriptase Polymerase Chain ReactionCoculture TechniquesTransplantation, HeterologousCell CountLymphoid Progenitor CellsAntigens, Thy-1Hematologic DiseasesMyeloid CellsPlant StemsGreen Fluorescent ProteinsCell SurvivalChemokine CXCL12Yolk SacMyelopoiesisSevere Combined ImmunodeficiencyMice, CongenicPhenotypeBlood CellsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteGene Expression Regulation, Developmental
TransplantationGVHDHSCTDiseaseChronicProgenitor cellsMalignanciesRecipientsUmbilical-cord2018ComplicationsProphylaxisMortalityImmuneIncidenceSevereAutologousCGVHDHostTransplant PatientsImmunologicalClinicalTransplantsImmunosuppressionAllogeneic stem cell transTherapyCitationMesenchymal StemMultipotentHaploidenticalInflammationAntigen preseTreatmentBoneLymphocytesPeripheralMyeloidVivoSecondary
Transplantation58
GVHD23
  • A team of hematology marrow transplant department of the Saint-Louis Hospital AP-HP, the Paris University and INSERM (U976 unit) in collaboration with the Pasteur Institute, led the work on graft against host disease (GVHD) using liquid chromatography coupled with mass spectrometry to study the metabolome of allogeneic patients at Saint-Louis hospital AP-HP. (pasteur.fr)
  • Graft against the host (GVHD) is a major complication that may occur after a allograft, and is characterized by tissue damage induced by donor immune cells which react against those of the recipient. (pasteur.fr)
  • Indoles derivatives are ligands of the receptor Aryl Hydrocarbon (AhR), which regulates the activation and differentiation of immune cells and could therefore contribute to limiting the risk of immune reaction to allogeneic origin of GVHD. (pasteur.fr)
  • These results published in the journal Nature Communications highlight the major changes in the human metabolome after allograft, associated with alterations of the patient's metabolism or its microbiota, which may represent potential therapeutic targets new for the prevention or treating the graft against the host (GVHD). (pasteur.fr)
  • However, there are many treatment -related complications , including organ disorders, graft-versus-host disease (GVHD), and infectious diseases . (bvsalud.org)
  • Vascular injury has been seen in patients with acute graft versus host disease (GVHD) in the skin. (nih.gov)
  • Perivascular CD8 T cell infiltrates in skin correlated with vWF plasma concentrations in patients with GVHD (p=0.01), and activated cytotoxic T lymphocytes and endothelial injury were present in these same samples. (nih.gov)
  • Graft-versus-host disease ( GvHD ) is a syndrome , characterized by inflammation in different organs. (wikipedia.org)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
  • GvHD can also occur after a blood transfusion , known as Transfusion-associated graft-versus-host disease or TA-GvHD if the blood products used have not been gamma irradiated or treated with an approved leukocyte reduction system. (wikipedia.org)
  • Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. (medscimonit.com)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • Although T-cell depletion (TCD) reduces the risk of GVHD after a myeloablative conditioning regimen, it is associated with an increased risk of graft failure. (qub.ac.uk)
  • Graft versus host disease (GVHD) represents the most frequent cause of TRM. (hindawi.com)
  • Shortly before graft infusion, GVHD prophylaxis (immunosuppression) is started. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). (nature.com)
  • We present a case of HLH secondary to graft vs host disease (GVHD) in a patient who underwent simultaneous liver-kidney transplant (SLKT). (asn-online.org)
  • Keywords: Hemophagocytic lymphohistiocytosis (HLH), graft versus host disease (GVHD). (asn-online.org)
  • Their relevance in terms of graft-versus-host disease (GVHD). (koreamed.org)
HSCT9
  • Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
  • On one end of the spectrum, invasive aspergillosis (IA) predominantly affects patients with profound defects in immune function, such as haematopoietic stem cell transplant (HSCT) or solid organ transplant recipients, and patients undergoing chemotherapy or taking corticosteroids. (bmj.com)
  • OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Takeda ( TSE:4502/NYSE:TAK ) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo. (businesswire.com)
  • Lower GI aGvHD represents a critical unmet need in patients undergoing allo-HSCT," said Yi-Bin Chen, MD, Director, Hematopoietic Cell Transplant & Cell Therapy Program, Mass General Cancer Center. (businesswire.com)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • Prior allogeneic hematopoietic stem cell transplant (HSCT) or donor lymphocyte infusion within 6 months prior to enrollment, current acute graft versus host disease grade 2-4 by Glucksberg criteria or severity B-D by by International Bone Marrow Transplant Registry (IBMTR) index or history of severe (grade 3-4) acute graft versus host disease. (moffitt.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
Disease58
  • Graft-versus-host disease is a potentially serious complication in a recipient of an allograft (usually a haematopoietic stem cell transplant) that arises from the attack of recipient tissues (such as the skin, liver or gut) by donor-derived T cells. (nature.com)
  • Not to be confused with Host-versus-graft disease . (wikipedia.org)
  • Mouse colon impacted by acute graft-versus-host disease. (wikipedia.org)
  • Micrographs of grades of skin graft-versus-host disease: Ranging from grade I GvHR (with minimal vacuolization in the epidermis) to grade II GvHR (with vacuolization and dyskeratotic bodies) to grade III GvHR (with sub epidermal cleft formation) and finally to grade IV GvHR (with separation of the dermis from the epidermis). (wikipedia.org)
  • In the clinical setting, graft-versus-host disease is divided into acute and chronic forms, and scored or graded on the basis of the tissue affected and the severity of the reaction. (wikipedia.org)
  • In the classical sense, acute graft-versus-host disease is characterized by selective damage to the liver , skin (rash), mucosa , and the gastrointestinal tract . (wikipedia.org)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system , e.g., the bone marrow and the thymus ) itself, and the lungs in the form of immune-mediated pneumonitis . (wikipedia.org)
  • [6] Chronic graft-versus-host disease also attacks the above organs, but over its long-term course can also cause damage to the connective tissue and exocrine glands . (wikipedia.org)
  • In the evolving landscape of graft-versus-host disease management, staying abreast of current and projected epidemiological trends is vital. (researchandmarkets.com)
  • Armed with historical and forecasted data, the report elucidates the severity and organ-specific grading of graft-versus-host disease cases. (researchandmarkets.com)
  • This comprehensive knowledge is paramount for informed decision-making and strategic planning in the quest to tackle graft-versus-host disease. (researchandmarkets.com)
  • Total allogenic transplant cases of graft-versus-host disease in the 7MM range from ~24,440 in 2022 to ~29,600 in 2032. (researchandmarkets.com)
  • Graft-versus-host disease is categorized into two types: acute and chronic graft-versus-host disease. (researchandmarkets.com)
  • In the 7MM, the acute graft-versus-host disease incident cases were ~10,340 in 2022, which are likely to increase to ~12,360 by 2032. (researchandmarkets.com)
  • Furthermore, in the 7MM, the 5-year prevalence of chronic graft-versus-host disease was ~23,080 in 2022, which is likely to increase to ~26,300 cases by 2032. (researchandmarkets.com)
  • An assessment of the degree of involvement of these organs determines the severity of acute graft-versus-host disease. (researchandmarkets.com)
  • The overall severity of chronic graft-versus-host disease is classified as mild, moderate, or severe based on organ-specific grading (number of organs and severity). (researchandmarkets.com)
  • Approximately ~45% of 5-year prevalent cases of chronic graft-versus-host disease belong to the moderate category. (researchandmarkets.com)
  • Skin (~59%), oral mucosa (~53%), eyes (~53%), lungs (~43%), liver (~29%), joints and fascia (~28%), and gastrointestinal (~23%) are the most often affected organs by chronic graft-versus-host disease. (researchandmarkets.com)
  • In 2022, the 7MM mortality-adjusted treated acute graft-versus-host disease patients were ~9,830 in first-line, and these cases are expected to increase to ~11,740 cases by 2032. (researchandmarkets.com)
  • This "Graft vs. Host Disease - Epidemiology Forecast - 2032" report delivers an in-depth understanding of Graft vs. Host Disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. (researchandmarkets.com)
  • The two main types of Graft vs. Host Disease are acute Graft vs. Host Disease and Chronic Graft vs. Host Disease. (researchandmarkets.com)
  • As an allogeneic transplant recipient, the patient might experience either form of Graft vs. Host Disease, either form, or neither. (researchandmarkets.com)
  • A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. (nature.com)
  • Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. (nature.com)
  • Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. (nature.com)
  • Dr. Cowen's primary research interest involves chronic graft-versus-host disease (cGVHD) and autoinflammatory diseases. (nih.gov)
  • This is chronic graft versus host disease. (nih.gov)
  • Quality of Life in Patients With Skin of Color and Chronic Graft-vs-Host Disease. (nih.gov)
  • Rehabilitation Interventions in the Multidisciplinary Management of Patients With Sclerotic Graft-Versus-Host Disease of the Skin and Fascia. (nih.gov)
  • Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. (nih.gov)
  • This is what life is often like every day for more than 6 million people worldwide who live with sickle cell disease (SCD). (aacn.org)
  • SCD, which includes sickle cell anemia, sickle cell beta thalassemia, sickle hemoglobin C disease and SCT, is an autosomal dominant genetic disorder that is passed from both parents to their children. (aacn.org)
  • Lack of donors and the risk of graft-versus-host disease or graft failure limits this option for many people. (aacn.org)
  • While working in these companies, Dr. Streeter led research efforts in the engineering of hematopoietic cytokines, the development of anti-tumor vaccines, and the identification of selective inhibitors of autoimmune disease. (ohsu.edu)
  • Merkel cell carcinoma, a rare type of skin cancer, is an aggressive and fast-growing disease that has been associated with mortality rates higher than other types of skin cancer, including melanoma," said Dr. (merck.com)
  • Fig. 1: Morbilliform rash, the most common skin manifestation of acute graft-vs-host disease. (ascopost.com)
  • Fig. 2: Follicular accentuation of skin lesions may be an early but important clinical clue during the development of acute graft-vs-host disease. (ascopost.com)
  • The cornerstone of treatment for acute graft-vs-host disease is the prophylactic regimen, but once cutaneous lesions develop, treatment is based on the stage of disease. (ascopost.com)
  • Acute graft-vs-host disease results from epithelial tissue damage following conditioning chemotherapy with subsequent infusion of competent donor lymphocytes within the allograft that result in damage to the skin, gut, and liver. (ascopost.com)
  • Acute graft-vs-host disease may occur either in isolation or in combination with intestinal or hepatic disease. (ascopost.com)
  • Skin biopsy may demonstrate interface dermatitis with necrotic keratinocytes, but its utility in diagnosing acute graft-vs-host disease is controversial. (ascopost.com)
  • Risk factors for acute graft-vs-host disease include histocompatibility antigen mismatch, older age of transplant recipient, total-body irradiation as a component of conditioning chemotherapy, gender mismatch between donor and recipient, and prior host exposure to blood products. (ascopost.com)
  • these include late-onset acute, recurrent acute, and persistent acute graft-vs-host disease. (ascopost.com)
  • Erythema of the ears or palms may herald the onset of acute graft-vs-host disease. (ascopost.com)
  • While a morbilliform appearance (Fig. 1) is the most common skin manifestation of acute graft-vs-host disease, other morphologies are well recognized and include violaceous lesions, reticulated variants, and severe forms that produce widespread desquamation that may mimic toxic epidermal necrolysis. (ascopost.com)
  • Ensuring that the calcineurin inhibitor used for graft-vs-host disease prophylaxis is within the serum therapeutic range, or restarting a systemic calcineurin inhibitor along with high-dose systemic steroids at the onset of stage II to IV acute graft-vs-host disease is preferred. (ascopost.com)
  • The application of topical steroids twice daily to moist skin and covered with warm wet towels as an occlusive measure ("wet wrap") is particularly effective for patients with diffuse skin graft-vs-host disease. (ascopost.com)
  • Extracorporeal photopheresis, an effective treatment for patients with chronic graft-vs-host disease, has recently been shown to benefit patients with steroid-refractory graft-vs-host disease. (ascopost.com)
  • T-cell responses correlate directly with clinical symptoms, and were better predictors of HHV-6 disease than viral load or total CD3+ counts. (hhv-6foundation.org)
  • Aerosolized formulations of amphotericin B may be considered as prophylaxis in patients with prolonged neutropenia (patients receiving induction/reinduction therapy for acute leukemia and allogeneic hematopoietic stem cell transplant recipients following conditioning or during treatment of graft versus host disease) and in lung transplant recipients. (medscape.com)
  • New devices have demonstrated significant results for the treatment of medical conditions, including mild-to-moderate acne vulgaris, wound healing, psoriasis, squamous cell carcinoma in situ (Bowen's disease), basal cell carcinoma, actinic keratosis, and cosmetic applications. (researchgate.net)
  • Joint contracture in chronic graft-versus-host disease (cGVHD) is refractory to treatment, and tends to deteriorate gradually over time. (koreamed.org)
  • High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype. (cdc.gov)
  • Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. (cdc.gov)
  • Covariance pattern models were used to determine predictors of regret over time, including baseline characteristics and post-alloHCT outcomes (acute or chronic graft-versus-host-disease, disease recurrence). (cdc.gov)
  • Gene and cell therapies present novel alternatives to disease management, offering the promise of a single treatment and a lifelong cure. (bvsalud.org)
  • Cell Replacement Therapy for Parkinson's Disease - Evaluating the potential of autologous grafting. (lu.se)
Chronic3
  • While pain can be acute, such as in a sickle cell crisis, people with SCD can also have chronic pain. (aacn.org)
  • In this paper, we review and present our new data of LED treatment on cells grown in culture, on ischemic and diabetic wounds in rat models, and on acute and chronic wounds in humans. (researchgate.net)
  • The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies. (moffitt.org)
Progenitor cells10
  • Stem and progenitor cells can be taken from the pelvis, at the iliac crest, using a needle and syringe. (wikipedia.org)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • Stem/progenitor cells offer the promise that transplantable beta cells may be generated in the laboratory. (ohsu.edu)
  • To deliver on that promise, our laboratory is collaborating with the laboratories of Markus Grompe, M.D., OHSU, and Gordon Keller, Ph.D., University Health Network, Toronto, Canada, in the development and characterization of monoclonal antibodies directed against cell surface molecules expressed by pancreatic cell subsets as well as pancreatic progenitor cells derived from pluripotent stem cells. (ohsu.edu)
  • This project focuses on the compelling need to generate cell-surface marker specific reagents useful for identification, study, and isolation of pulmonary stem/progenitor cells. (ohsu.edu)
  • Omidubicel is made from umbilical cord donor stem cells that are processed with nicotinamide, a form of vitamin B3, to enhance and expand the number of progenitor cells, the product's maker, Israel-based Gamida Cell, explained in a press announcement . (medscape.com)
  • Early fate decisions in hematopoietic stem and progenitor cells. (lu.se)
Malignancies3
  • Allogeneic hematopoietic stem cell (HSC) is a curative treatment used for many hematologic malignancies and congenital or acquired anomalies of hematopoiesis. (pasteur.fr)
  • Abbey Jenkins, president and CEO of Gamida, called the approval "a major advancement in the treatment of patients with hematologic malignancies that we believe may increase access to stem cell transplant and help improve patient outcomes. (medscape.com)
  • Detection of galactomannan (a component of the Aspergillus cell wall) in serum or bronchoalveolar lavage fluid is recommended as an accurate marker for the diagnosis of invasive aspergillosis in adults and children, when used in certain patient subpopulations, such as hematopoietic stem cell transplant recipients or patients with hematologic malignancies. (medscape.com)
Recipients2
  • high-risk patients included male subjects, recipients of stem cells from female donors, patients younger than 10 years, those with nonidentical donors, and those who received radiation therapy in the transplant preparative regimen. (medscape.com)
  • The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only and adults who are hematopoietic stem cell transplant recipients. (cdc.gov)
Umbilical-cord1
  • The US Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for reducing infections and hastening neutrophil recovery for blood cancer patients aged 12 years and older who are undergoing allogeneic umbilical cord blood stem cell transplants. (medscape.com)
20181
  • Hematology, transfusion and cell therapy 2018 7 40 (2): 136-142. (cdc.gov)
Complications2
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • Could some complications of CAR-T cell therapy be secondary to HHV-6 infection? (hhv-6foundation.org)
Prophylaxis1
  • Medications are used for prophylaxis against viral and fungal infections, decontamination of the oral cavity, and palliation for pain. (medscape.com)
Mortality1
  • Broader use has been hampered for a long time mainly by high non-relapse mortality, offsetting the advantage of a graft-vs-lymphoma effect. (nih.gov)
Immune5
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • As an intergenic lncRNA, the lncDC was shown to regulate the human monocytes differentiation and antigen presenting cells (APCs) activation during immune responses. (magiran.com)
  • Immune cells from the donor may see the body tissues in the person as foreign and attack, causing damage. (nih.gov)
  • KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. (merck.com)
  • Shimano KA, Grace RF, Despotovic JM, Neufeld EJ, Klaassen RJ, Bennett CM, Ma C, London WB, Neunert C. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. (ucsf.edu)
Incidence1
  • The incidence of grade 2/3 bacterial or grade 3 fungal infections 100 days following transplant was 39% with omidubicel, vs 60% with standard transplants. (medscape.com)
Severe2
  • Sickle cell anemia, the most severe form of SCD, occurs when both sickle cell genes (hemoglobin S or Hb S ) are inherited from each parent. (aacn.org)
  • His cell counts, kidney function and liver tests were within normal range at admission but he later developed severe pancytopenia and a very high ferritin (15,910 ng/mL). (asn-online.org)
Autologous1
  • Resource utilization and toxicities after carboplatin/etoposide/melphalan and busulfan/melphalan for autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. (chop.edu)
CGVHD1
  • About half the people who have a hematopoietic stem cell transplant using donor cells get cGVHD. (nih.gov)
Host1
  • Host endothelial cells are a target of alloreactive donor cytotoxic T lymphocytes. (nih.gov)
Transplant Patients1
  • A Pilot Trial of Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Pediatric Hematopoietic Stem Cell Transplant Patients. (ucsf.edu)
Immunological2
  • providing evidence for an immunological graft-versus-leukemia effect (GvL). (frontiersin.org)
  • Immunological and translational aspects of NK cell-based antitumor immunotherapies. (springer.com)
Clinical4
  • Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy-covering virtually all aspects of hematology in one definitive resource. (elsevierhealth.com)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • Shimano KA, Vanderpoel V, Stone H, Resar L, Kucine N. Clinical features associated with thrombotic events in children with myeloproliferative neoplasms. (ucsf.edu)
  • Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. (cdc.gov)
Transplants3
  • The FDA approval was based on phase 3 testing that pitted the use of omidubicel in 62 patients against standard unmanipulated cord blood transplants in 63 patients following myeloablative conditioning. (medscape.com)
  • Overall, 87% of patients who received omidubicel achieved neutrophil recovery, vs 83% of patients with standard transplants. (medscape.com)
  • HLH has also been reported after kidney, liver and hematopoietic stem cell transplants. (asn-online.org)
Immunosuppression1
  • 200 cells/ml, indicating substantial immunosuppression. (cdc.gov)
Allogeneic stem cell trans1
  • Before undergoing an allogeneic stem cell transplant, the patient will receive high doses of chemotherapy or radiation to destroy the diseased cells and prepare the body for the donor cells. (researchandmarkets.com)
Therapy12
  • Understanding of molecular mechanisms in natural killer cell therapy. (springer.com)
  • 2014). Human NK cells: From surface receptors to the therapy of leukemias and solid tumors. (springer.com)
  • However, the supply of donor-derived islets will never meet the needs of the large number of patients who could potentially benefit from this cell-based therapy. (ohsu.edu)
  • License Application (sBLA) seeking accelerated approval for KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). (merck.com)
  • KEYNOTE-017 represents the longest observation to date of patients with advanced Merkel cell carcinoma receiving anti-PD-1 therapy in the first-line setting, and demonstrated durable tumor control in these patients. (merck.com)
  • The FDA's "approval is an important advance in cell therapy treatment in patients with blood cancers. (medscape.com)
  • Cite this: FDA OKs Stem Cell Therapy to Reduce Infection Risk in Blood Cancer Patients - Medscape - Apr 18, 2023. (medscape.com)
  • A growing number of case reports reveal reactivation similar to that seen after hematopoietic stem cell therapy. (hhv-6foundation.org)
  • Might HHV-6 contribute to some cases of cytokine release syndrome, pneumonia, and cytopenias in CAR-T Cell therapy? (hhv-6foundation.org)
  • CheckMate -67T is a Phase 3 randomized, open-label trial evaluating subcutaneous administration of Opdivo co-formulated with Halozyme's proprietary recombinant human hyaluronidase, rHuPH20, or subcutaneous nivolumab (nivolumab and hyaluronidase) compared to intravenous (IV) Opdivo , in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy. (businesswire.com)
  • The current gold standard of care for first-line therapy in patients with nonsmall cell lung cancer (NSCLC) is a platinum-based doublet chemotherapy, which is recommended for a maximum of six cycles. (deepdyve.com)
  • Echinocandins are effective in salvage therapy (either alone or in combination) against invasive aspergillosis, but they are not recommended for routine use as monotherapy for the primary treatment of invasive aspergillosis. (medscape.com)
Citation2
Mesenchymal Stem1
  • Wharton's jelly mesenchymal stem cells (WJ-MSCs) are a class of stem cells with high differentiative potential, an immuno-privileged status and easy access for collection, which raise no legal or ethical. (koreamed.org)
Multipotent4
Haploidentical1
  • Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). (frontiersin.org)
Inflammation1
  • Inflammation and endothelial injury were assessed in selected samples by immunostaining for CD8 T cells, activated cytotoxic T lymphocytes, and vascular endothelial cells. (nih.gov)
Antigen prese1
  • NK expansion and activation were stimulated by culture with artificial antigen-presenting cells (aAPCs) and IL-2, in the presence or absence of BM-MSCs. (springer.com)
Treatment3
  • Treatment-related adverse events were reported in 24.8% versus 28.4%, and treatment related serious adverse events in 8.5% versus 6.5% of patients treated with placebo versus vedolizumab, respectively. (businesswire.com)
  • Areas of research focus are beta cell replacement therapies for the treatment of diabetes, the identification of lung progenitor cell populations involved in lung repair, and in the diagnosis of pancreatic cancer. (ohsu.edu)
  • KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. (merck.com)
Bone4
  • This bone marrow film at 400X magnification demonstrates a complete absence of hemopoietic cells. (medscape.com)
  • Hematopoietic stem cells are found in the bone marrow of adults, especially in the pelvis, femur, and sternum. (wikipedia.org)
  • The cells can be removed as liquid (to perform a smear to look at the cell morphology) or they can be removed via a core biopsy (to maintain the architecture or relationship of the cells to each other and to the bone). (wikipedia.org)
  • Another CFU, the colony-forming unit-spleen (CFU-S), was the basis of an in vivo clonal colony formation, which depends on the ability of infused bone marrow cells to give rise to clones of maturing hematopoietic cells in the spleens of irradiated mice after 8 to 12 days. (wikipedia.org)
Lymphocytes4
  • Most of the identifiable cells are lymphocytes or plasma cells. (medscape.com)
  • In shape, hematopoietic stem cells resemble lymphocytes. (wikipedia.org)
  • PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. (merck.com)
  • Інфекція вірусом імунодефіциту людини (ВІЛ) Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain. (msdmanuals.com)
Peripheral2
Myeloid3
Vivo1
  • Shaping of natural killer cell antitumor activity by ex vivo cultivation. (springer.com)
Secondary1
  • Additionally, subcutaneous nivolumab showed a noninferior objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) vs. IV Opdivo , a key secondary endpoint. (businesswire.com)